Suven Life Sciences granted new patents

Patents cover drugs for treating neurodegenerative disorders

Suven Life Sciences, a biopharmaceutical company, has secured product patents from Israel, Japan and South Africa corresponding to its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven, which are being developed as therapeutic agents for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson's and schizophrenia.

With these new patents, Suven now has a total of six granted patents from Israel, 17 from Japan and 20 from South Africa. These granted patents are the exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out licensed at various phases of clinical development, the company has said.